Clik here to view.
Cancer drugs shouldn’t just extend life…
As someone who lost both parents to cancer the one lesson that I learned from their many years of treatment is that for them “the treatments were not worth the benefits”. My mother especially had told...
View ArticleClik here to view.
We sell cancer drugs, we don’t need a patient website
More and more I am finding that patients who face with a dizzying amount of treatment options when it comes to fighting cancer that they are often forced to look at other websites because patient...
View ArticleClik here to view.
Viewing cancer patients as people not a market segment
Via and Eye for Pharma article according to the recently released Ipsos report, Oncologists are prioritising patient ‘quality of life’ (94%) and patient affordability and product cost (65%) when they...
View ArticleClik here to view.
Cancer Patients: Cost is an issue when thinking about treatments
In a Milliman Medical Index survey released in May, physician and other professional services for an average family of four that receives health care benefits through an employer-sponsored preferred...
View ArticleClik here to view.
Extending the lives of cancer patients, but at what cost ?
The Food and Drug Administration on Friday approved Celgene’s drug Abraxane for use in treating advanced pancreatic cancer which in clinical trials prolonged the lives of patients by a little less than...
View ArticleClik here to view.
Cost vs. benefit of cancer drugs
“Is a $30,000-a-month drug that improves survival by 1.4 months effective? At the ASCO meeting this week, that dialog has already begun. In a forum on drug costs, Dr. Ezekiel Emanuel, The architect of...
View ArticleClik here to view.
No amount of innovation can justify the doubling of prices for cancer drugs
POST SUMMARY: The number of over-65s on the planet is projected almost to triple between 2010 and 2050 to 1.5bn, according to the UN. This, in turn, will spur a surge in age-related diseases such as...
View ArticleClik here to view.
Pharma ignores patients as new cancer drug data are released
62 percent of cancer patients report being in debt due to their treatment. 55 percent accrue at least $10,000 in debt, while 3 percent file for bankruptcy. Cancer costs exceed $80 billion in America...
View ArticleClik here to view.
The promise of accelerated approval of cancer drugs
KEY TAKEAWAY: Few cancer drugs approved via the accelerated FDA approval pathway were judged to have verified benefits based on improvement in survival reported in confirmatory trials. Many cancer...
View ArticleClik here to view.
Can we get healthcare right?
Imbruvica, a cancer medication, carries a wholesale price of about $16,000 a month. Patients on Medicare who don’t qualify for low-income subsidies could see out-of-pocket costs for the drug of over...
View ArticleClik here to view.
About that cancer moonshot
A “cancer moonshot” refers to an ambitious effort to accelerate progress in cancer research and treatment, drawing inspiration from the determination and focus that drove the United States moon landing...
View ArticleClik here to view.
What’s causing the cancer drug shortage?
The nation’s monthslong shortage of highly potent cancer drugs is grinding on, forcing patients and their doctors to face even grimmer realities than that cancer typically presents. Several factors...
View Article
